Earth Science Tech, Inc. (ETST) Finalizes Plans for Human Trials on New CBD-Based Formula Targeting Opioid Addiction Epidemic

Earth Science Tech, Inc. (OTC: ETST), an innovative biotech company focused on the cannabinoid (“CBD”), nutraceutical and pharmaceutical fields, as well as on R&D for certain medical devices, today announces that it has finalized the plans for its previously announced human trial to assess the efficacy of the combination of an essential mineral element and full-spectrum cannabinoid industrial hemp oil. The purpose of this nine-month trial is to develop a CBD formulation and methodology for treating opioid addicts, preventing fatal overdoses, and relieving side-effects from withdrawals.